ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
-4.37%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$520M
AUM Growth
+$520M
(+7.1%)
Cap. Flow
+$56.8M
Cap. Flow
% of AUM
10.93%
Top 10 Holdings %
Top 10 Hldgs %
45.71%
Holding
253
New
46
Increased
68
Reduced
40
Closed
49
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$14.9M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$9.17M |
| 3 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
$8.55M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.34M |
| 5 |
RAPT Therapeutics
RAPT
|
$5.85M |
Top Sells
| 1 |
BridgeBio Pharma
BBIO
|
$11.7M |
| 2 |
Ascendis Pharma
ASND
|
$10.9M |
| 3 |
Mineralys Therapeutics
MLYS
|
$9.18M |
| 4 |
EDR
Endeavor Group Holdings, Inc.
EDR
|
$6.59M |
| 5 |
Sanofi
SNY
|
$4.8M |
Sector Composition
| 1 | Healthcare | 80.96% |
| 2 | Financials | 3.59% |
| 3 | Consumer Discretionary | 0.06% |
| 4 | Utilities | 0.02% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Protagonist Therapeutics
PTGX
$3.67B
| $45.4M | 8.44% | 939,669 -80,664 | -8% | -$3.9M |
|
2
Alpha Architect 1-3 Month Box ETF
BOXX
$7.91B
| $37.6M | 6.98% | 337,125 +11,675 | +4% | +$1.3M |
|
3
Roivant Sciences
ROIV
$8.15B
| $35.1M | 6.52% | 3,483,404 -25,290 | -0.7% | -$255K |
|
4
Zai Lab
ZLAB
$3.68B
| $34M | 6.31% | 940,858 -104,979 | -10% | -$3.79M |
|
5
Immunovant
IMVT
$2.56B
| $16.6M | 3.07% | 968,866 +181,388 | +23% | +$3.1M |
|
6
Cytokinetics
CYTK
$4.23B
| $15.7M | 2.92% | 390,729 -23,480 | -6% | -$944K |
|
|
7
Keros Therapeutics
KROS
$618M
| $15.1M | 2.81% | 1,486,461 +1,463,215 | +6,294% | +$14.9M |
|
|
ABVX
8
Abivax
ABVX
$6.12B
| $13.8M | 2.56% | 2,210,019 +696,626 | +46% | +$4.35M |
|
9
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$42.1B
| $12.4M | 2.31% | 135,585 +3,799 | +3% | +$348K |
|
|
10
BridgeBio Pharma
BBIO
$9.89B
| $11.7M | 2.18% | 339,635 -339,222 | -50% | -$11.7M |
|
11
Inhibikase Therapeutics
IKT
$134M
| $11.2M | 2.08% | 5,122,105 +19,100 | +0.4% | +$41.8K |
|
|
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
| $9.17M | 1.7% | +207,778 | New | +$9.17M |
|
|
13
iShares 1-3 Year Treasury Bond ETF
SHY
$24.5B
| $8.55M | 1.59% | +103,337 | New | +$8.55M |
|
14
Teva Pharmaceuticals
TEVA
$21.1B
| $8.05M | 1.49% | 523,767 +377,096 | +257% | +$5.8M |
|
15
Sarepta Therapeutics
SRPT
$1.78B
| $7.84M | 1.46% | 122,921 +82,919 | +207% | +$5.29M |
|
|
PCSC
16
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.73M | 1.43% | 750,000 | – | – |
|
17
CG Oncology
CGON
$2.04B
| $7.37M | 1.37% | 301,134 +85,384 | +40% | +$2.09M |
|
|
18
RAPT Therapeutics
RAPT
$188M
| $7.28M | 1.35% | 5,970,768 +4,796,455 | +408% | +$5.85M |
|
19
Arbutus Biopharma
ABUS
$711M
| $6.56M | 1.22% | 1,879,114 +324,312 | +21% | +$1.13M |
|
|
ITCI
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.34M | 1.18% | +48,044 | New | +$6.34M |
|
21
Revolution Medicines
RVMD
$7.1B
| $6.26M | 1.16% | 177,136 +7,136 | +4% | +$252K |
|
|
AVR
22
Anteris Technologies Global Corp. Common Stock
AVR
$145M
| $6.11M | 1.13% | 1,678,063 +625,095 | +59% | +$2.28M |
|
|
AAM
23
AA Mission Acquisition Corp.
AAM
$462M
| $6.03M | 1.12% | 578,359 +18,160 | +3% | +$189K |
|
|
SAGE
24
DELISTED
Sage Therapeutics
SAGE
| $5.9M | 1.1% | 742,495 +723,295 | +3,767% | +$5.75M |
|
25
89bio
ETNB
$1.34B
| $5.85M | 1.09% | 804,220 +289,082 | +56% | +$2.1M |
|